Navigation Links
Piramal imaging to present data at Society for Nuclear Medicine Annual Meeting
Date:6/8/2012

Miami Beach, Fla., June 8, 2012: Piramal Imaging SA, a subsidiary of Piramal Healthcare Limited [NSE: PIRHEALTH, BSE: 500302], will present data on several compounds from its molecular imaging portfolio at the Society of Nuclear Medicine's 59th annual meeting in Miami Beach, Fla., from June 9 - 13. Data from five florbetaben studies will be featured, including results from a pivotal Phase III trial which will provide the basis for regulatory submission later this year.

Earlier this spring, Piramal Imaging was formed through the acquisition of worldwide rights to the molecular imaging research and development portfolio of Bayer Pharma AG. Florbetaben, a late-stage amyloid imaging agent being studied as a potential tool to aid in the diagnosis and assessment of Alzheimer's disease, is the lead compound in the portfolio.

Historically, the only way to definitively diagnose Alzheimer's disease has been after death at autopsy through analysis and identification of beta-amyloid in brain tissue. The global Phase III trial employed a unique and rigorous study design comparing in vivo brain positron emission tomography (PET) imaging with florbetaben to post-mortem analysis of the brain tissue. Another study compared florbetaben scans of people with mild cognitive impairment (MCI) over time to assess their risk of developing Alzheimer's disease.

"What better way to introduce Piramal Imaging to the nuclear medicine community," says Dr. Ludger M. Dinkelborg, CEO Piramal Imaging. "We believe we have the richest molecular imaging portfolio in the industry today, and the range of research we are presenting here reflects the depth, diversity and clinical relevance of our pipeline." Before co-founding Piramal Imaging, Dr. Dinkelborg served as Head of Diagnostic Imaging Research and Head of Molecular Imaging at Bayer Healthcare.

Piramal Imaging is developing an innovative and proprietary tracer portfolio to address major clinical needs in Alzheimer's disease, prostate cancer, lung cancer, liver cancer, and cardiovascular disease.

"Our goal is to be a leader in molecular imaging through increased diagnostic accuracy of serious medical conditions to improve patient care," says Dr. Swati A. Piramal, Director, Piramal Healthcare Limited. "On a parallel track with our aggressive clinical development program, we are taking the necessary steps toward bringing our tracers to market through the formation of strategic partnerships." Dr. Piramal was recently elected to the Harvard Board of Overseers and also serves on the Dean's Advisory Board of both the Harvard School of Public Health and Harvard Business School.

At this meeting, research on several of the company's pipeline compounds will be featured, including:

NOTE TO EDITORS: All data is embargoed until the date/time of presentation.

Florbetaben

Multicentre phase 3 trial on florbetaben for β-amyloid brain PET in Alzheimer disease [Abstract #41]
Oral Presentation: Neuroscience Miscellaneous & New Approaches
Sunday, June 10, 1:57 PM - 2:09 PM, Room B217/218
Presenter: Osama Sabri, University of Leipzig, Leipzig, Germany

Longitudinal assessment of cerebral amyloid-β deposition in APP-Swe mice with [18F]florbetaben PET [Abstract #92]
Oral Presentation: Brain Imaging Council Young Investigator Award Symposium
Sunday, June 10, 5:03 PM - 5:15 PM, Room B217/218
Presenter: Axel Rominger, University of Munich, Munich, Germany

Partial volume effect correction of florbetaben β-amyloid (Aβ) PET data improves discrimination between Alzheimer's disease (AD) patients and healthy volunteers (HVs) [Abstract #146]
Oral Presentation: Quantifying Brain Amyloid Signal - Methods & Challenges
Monday, June 11, 10:24 AM - 10:36 AM, Room B217/218
Presenter: Henryk Barthel, University of Leipzig, Leipzig, Germany

A two-year longitudinal assessment of Aβ deposition in MCI with 18F-Florbetaben [Abstract #148]
Oral Presentation: Quantifying Brain Amyloid Signal - Methods & Challenges
Monday, June 11, 10:48 AM - 11:00 AM, Room B217/218
Presenter: Kevin Ong, Centre for PET, Austin Health, Melbourne, VIC, Australia

In vivo PET imaging of β-amyloid plaques in an APP/PS1 mouse model of Alzheimer's disease: Comparison of [18F]FIBT and [18F]Florbetaben with [11C]PiB [Abstract #1630]
Poster Presentation: Probes for Neuroimaging
Sunday, June 10, 7:04 PM - 7:06 PM, Exhibit Hall A-B
Presenter: Behrooz Hooshyar Yousefi, Technische Universitt Mnchen, Munich, Germany

FSPG

Correlation of (4S)-4-(3-[18F]fluoropropyl)-L-glutamate ([18F]FSPG) uptake by positron emission tomography (PET) with immunohistochemical expression of system xC- and CD44 in cancer patients [Abstract #219]
Oral Presentation: Basic Science (Oncology); Tumor Characterization & Microenvironment
Monday, June 11, 5:18 PM - 5:30 PM, Room B118/119
Presenter: Dae Hyuk Moon, University of Ulsan College of Medicine, Seoul, Republic of Korea

Evaluation of the 18F L-glutamate derivative 18F-FSPG (BAY 94-9392) in lymphoma and colon cancer patients [Abstract #1126]
Poster Presentation: Meet the Author Poster Session; Basic Science (Oncology)
Monday, June 11, 2:30 PM - 4:00 PM, Exhibit Hall A-B
Presenter: Meena Kumar, Stanford University Medical Center, Palo Alto, California, USA

Evaluation of the 18F-labeled L-glutamate derivative 18F-FSPG (BAY 94-9392) in brain and head and neck cancer patients [Abstract #274]
Oral Presentation: Basic Science (Oncology); Novel Imaging Agents - Clinical
Tuesday, June 12, 8:36 AM - 8:48 AM, Room B118/119
Presenter: Meena Kumar, Stanford University Medical Center, Palo Alto, California, USA

Characterization of physiological 18F-FSPG uptake in healthy volunteers: Kinetics and biodistribution [Abstract #555]
Oral Presentation: Technological Advances, Methodology, Quantification
Wednesday, June 13, 10:33 AM - 10:45 AM, Room B118/119
Presenter: Camila Mosci, Stanford University, Palo Alto, California, USA

Ga68-Bombesin
Preclinical validation of the Ga-68-Bombesin Antagonist BAY 86-7548 for a Phase I Study in Prostate Cancer Patients [Abstract #177]
Oral Presentation: Prostate
Monday, June 11, 12:30 PM - 12:42 PM, Room B214
Presenter: Sandra Borkowski, Global Drug Discovery, Bayer Healthcare, Berlin, Germany

Radiosynthesis and pre-clinical evaluation of Al18F labeled bombesin antagonist: Promising tracer for prostate cancer imaging [Abstract #1732]
Poster Presentation: Special Meet the Author Poster Session; Probes for Oncology
Sunday, June 10, 6:30 PM - 8:00 PM, Exhibit Hall A-B
Presenter: Svetlana Selivanova, Center for Radiopharmaceutical Sciences, ETH Zurich, Zurich, Switzerland

DFMT

Clinical investigation of dynamic PET/CT imaging using O-([18F]fluoromethyl)-D-tyrosine (D-18F-FMT, BAY 86-9596) in oncological patients [Abstract #1676]
Poster Presentation: Special Meet the Author Poster Session; Probes for Oncology
Sunday, June 10, 6:30 PM - 8:00 PM, Exhibit Hall A-B
Presenter: Irene Burger, University Hospital, Zurich, Switzerland

Comparison of PET/CT images with a novel tracer O-([18F]fluoromethyl)-D-tyrosine (D-18F-FMT, BAY 86-9596) with LAT1 immunohistochemical staining in patients with non-small cell lung cancer or head and neck squamous cell carcinoma [Abstract #1677]
Poster Presentation: Special Meet the Author Poster Session; Probes for Oncology
Sunday, June 10, 6:30 PM - 8:00 PM, Exhibit Hall A-B
Presenter: Irene Burger, University Hospital, Zurich, Switzerland


'/>"/>
Contact: Julie Armour
julie.armour@ketchum.com
908-656-5887
Ketchum New York
Source:Eurekalert

Related medicine news :

1. Fox Chase researchers find no disparities in imaging before breast cancer surgery
2. Study examines necessity of additional imaging in PET/CT oncologic reports
3. Low-dose whole-body CT finds disease missed on standard imaging for patients with multiple myeloma
4. Use of dedicated pediatric imaging departments for pediatric CT reduces radiation dose
5. MR enterography is as good or better than standard imaging exams for pediatric Crohns patients
6. Live imaging shows response to cancer drugs can be boosted by altering tumor microenvironment
7. Lung changes are present in nearly half of ACPA positive RA patients at disease onset
8. University Hospitals Case Medical Center experts present at ASCO Annual Meeting
9. Patient mental health overlooked by physician when a family member is present
10. SLEEP 2012 presents latest in sleep medicine and research June 11-13 in Boston
11. Mayo Clinic urologists present findings at American Urological Association Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology: